{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:18:20Z","timestamp":1762078700259},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T00:00:00Z","timestamp":1118361600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T00:00:00Z","timestamp":1118361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>The neuropeptide somatostatin is one of the major regulatory peptides in the central nervous system and the digestive tract. Our recent work has delineated an association between fibrosis and low levels of endogenous somatostatin plasma levels in <jats:italic>Schistosoma mansoni<\/jats:italic> infected subjects. Based on these results this paper explores the therapeutic potential of somatostatin in a mouse model of hepatic fibrosis associated with <jats:italic>S. mansoni<\/jats:italic> infections.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Groups of outbred Swiss mice were infected with 100 <jats:italic>S. mansoni<\/jats:italic> cercariae, infection maintained till weeks 10 or 14, and then somatostatin therapy delivered in two regimens \u2013 Either a one or a two-day treatment. All animals were sacrificed one week after therapy and controlled for liver, spleen and total body weight. Circulating somatostatin levels in mice plasma were measured at the time of sacrifice by means of a radio-immuno assay. GraphPad Prism<jats:sup>\u00ae<\/jats:sup> was used for statistical calculations.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Somatostatin administration showed little toxicity, probably due to its short half-life. Total liver and spleen weights of <jats:italic>S. mansoni<\/jats:italic> infected animals increased over time, with no changes observed due to somatostatin therapy. Total body weights were decreased after infection but were not affected by somatostatin therapy. Snap frozen liver sections were stained with haematoxylin-eosin or Masson's trichrome to study parasite count, hepatocyte status, granuloma size and cellularity. After somatostatin treatment mean egg counts per liver section (43.76 \u00b1 3.56) were significantly reduced as compared to the egg counts in untreated mice after 10 weeks of infection (56.01 \u00b1 3.34) (<jats:italic>P<\/jats:italic> = 0.03). Similar significant reduction in parasite egg counts were also observed after somatostatin treatment at 14 weeks of infection (56.62 \u00b1 3.02) as compared to untreated animals (69.82 \u00b1 2.77)(<jats:italic>P<\/jats:italic> = 0.006). Fibrosis was assessed from the spectrophotometric determination of tissue hydroxyproline. Infection with <jats:italic>S. mansoni<\/jats:italic> caused increased hydroxyproline levels (9.37 \u00b1 0.63 \u03bcmol at wk10; 9.65 \u00b1 0.96 \u03bcmol at wk14) as compared to uninfected animals (1.06 \u00b1 0.10 \u03bcmol). This significant increase in collagen content (<jats:italic>P<\/jats:italic> = 0.01; 0.007 respectively) marks the fibrosis observed at these time points. Treatment with somatostatin resulted in a significant decrease in hydroxyproline levels both at wk10 (4.76 \u00b1 0.58 \u03bcmol) and at wk14 (5.8 \u00b1 1.13 \u03bcmol) (<jats:italic>P<\/jats:italic> = 0.01; 0.03 respectively). Endogenous somatostatin levels were increased at wk10 (297 \u00b1 37.24 pg\/ml) and wk14 (206 \u00b1 13.30 pg\/ml) of infection as compared to uninfected mice (119 \u00b1 11.99 pg\/ml) (<jats:italic>P<\/jats:italic> = 0.01; 0.008 respectively). Circulating somatostatin levels in infected animals were not significantly affected by somatostatin treatment. Hepatocyte status remained unaltered and granulomas were not remarkably changed in size or cellularity.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Our experiments reveal an antifibrotic effect of somatostatin in schistosomiasis. We have previously shown that the somatostatin receptors SSTR2 and SSTR3 are present on the parasite egg and worms. We therefore hypothesize that somatostatin reduces either the number of parasite eggs or the secretion of fibrosis inducing-mediators. Our data suggest somatostatin may have therapeutic potential in <jats:italic>S. mansoni<\/jats:italic> mediated liver pathology.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-2334-5-45","type":"journal-article","created":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T18:13:38Z","timestamp":1118427218000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis"],"prefix":"10.1186","volume":"5","author":[{"given":"Shyama","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunther","family":"Vrolix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Depoortere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Marck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,6,10]]},"reference":[{"key":"193_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.actatropica.2003.12.002","volume":"90","author":"S Chatterjee","year":"2004","unstructured":"Chatterjee S, Mbaye A, Alfidja AT, Weyler J, Scott JT, Van Damme P, Van De Vijver K, Deelder A, Van Marck EAE: Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections. Acta Trop. 2004, 90: 191-203. 10.1016\/j.actatropica.2003.12.002.","journal-title":"Acta Trop"},{"key":"193_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0140-6736(97)05099-X","volume":"350","author":"A Avgerinos","year":"1997","unstructured":"Avgerinos A, Nevens F, Raptis S, Fevery J: Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomized trial. Lancet. 1997, 350: 1495-1499. 10.1016\/S0140-6736(97)05099-X.","journal-title":"Lancet"},{"key":"193_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/gut.35.10.1389","volume":"35","author":"HJ Lin","year":"1994","unstructured":"Lin HJ, Perng CL, Lee FY, Lee CH, Lee SD: Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study. Gut . 1994, 35: 1389-1393.","journal-title":"Gut"},{"key":"193_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0016-5107(98)70318-9","volume":"47","author":"JM Bordas","year":"1988","unstructured":"Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Gines A, Teres J: Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastroint Endosc. 1988, 47: 230-234.","journal-title":"Gastroint Endosc"},{"key":"193_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0210-5705(01)70177-X","volume":"24","author":"F Borda","year":"2001","unstructured":"Borda F, Jimenez FJ, Villa J: Cost-effectiveness study on the use of somatostatin for reduction of acute pancreatitis after ERCP. Gastroentero Hepatol. 2001, 24: 292-296.","journal-title":"Gastroentero Hepatol"},{"key":"193_CR6","first-page":"265","volume":"17","author":"GF Cicero","year":"1985","unstructured":"Cicero GF, Laugier R, Sahel J, Manganaro M, Sarles H: Effects of somatostatin on clinical, biochemical and morphological changes following ERCP. Int J Gastroenterol. 1985, 17: 265-268.","journal-title":"Int J Gastroenterol"},{"key":"193_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/0035-9203(69)90122-9","volume":"63","author":"AW Cheever","year":"1969","unstructured":"Cheever AW: Quantitative comparison of the intensity of Schistosoma mansoni infection in man and experimental animals. Trans R Soc Trop Med. 1969, 63: 781-795. 10.1016\/0035-9203(69)90122-9.","journal-title":"Trans R Soc Trop Med"},{"key":"193_CR8","first-page":"389","volume":"132","author":"ZA Andrade","year":"1988","unstructured":"Andrade ZA, Grimaud J-A: Morphology of chronic collagen resorption (a study on the late stages of schistosomal granuloma involution. Am J Path. 1988, 132: 389-399.","journal-title":"Am J Path"},{"key":"193_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1590\/S0074-02761987000800010","volume":"82","author":"J-A Grimaud","year":"1987","unstructured":"Grimaud J-A: Cell-matrix interactions in schistosomal portal fibrosis: a dynamic event. Mem Inst Oswaldo Cruz. 1987, 82: 55-65.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"193_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0014-4800(89)90049-X","volume":"50","author":"LC Da Silva","year":"1989","unstructured":"Da Silva LC, Mourao PA, Borojevic R: Patterns of sulfated glycosaminoglycan synthesis and accumulation in hepatic granulomas induced by Schistosomal infection. Exp Mol Pathol. 1989, 50: 411-420. 10.1016\/0014-4800(89)90049-X.","journal-title":"Exp Mol Pathol"},{"key":"193_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/BF01966002","volume":"36","author":"EA Van Marck","year":"1980","unstructured":"Van Marck EA, Stocker S, Grimaud JA, Kestens L, Gigase PL, Deelder AM: The implantation of sepharose beads in mouse livers as an aid in the study of hepatic schistosomal fibrosis. Experientia. 1980, 36: 1116-1118.","journal-title":"Experientia"},{"key":"193_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0168-8278(01)80893-X","volume":"34","author":"H Reynaert","year":"2001","unstructured":"Reynaert H, Vaeyens F, Rombouts K, Chatterjee N, Urbain D, Geerts A: Effect of somatostatin-14 on extracellular matrix expression by activated rat hepatic stellate cells. J Hepatol. 2001, 34: 6-","journal-title":"J Hepatol"},{"key":"193_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1471-4922(02)02294-8","volume":"18","author":"S Chatterjee","year":"2002","unstructured":"Chatterjee S, Mbaye A, De Man J, Van Marck E: Does the neuropeptide somatostatin have a therapeutic role in schistosomiasis?. Trends Parasitol. 2002, 18: 295-298. 10.1016\/S1471-4922(02)02294-8.","journal-title":"Trends Parasitol"},{"key":"193_CR14","volume-title":"Acta Leidensia","author":"EAE Van Marck","year":"1983","unstructured":"Van Marck EAE: The glomerulopathy associated with Schistosoma mansoni infection. An experimental study in the mouse. Acta Leidensia. 1983, 50:"},{"key":"193_CR15","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1021\/ac60205a053","volume":"35","author":"I Bergman","year":"1963","unstructured":"Bergman I, Loxley R: Two improved and simplified methods for spectrophotometric determination of hydroxyproline. Analyt Chem. 1963, 35: 1961-1965. 10.1021\/ac60205a053.","journal-title":"Analyt Chem"},{"key":"193_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4269\/ajtmh.1987.37.85","volume":"37","author":"AW Cheever","year":"1987","unstructured":"Cheever AW, Duvall RH, Hallack TA, Minker RG, Malley JD, Malley KG: Variations of hepatic fibrosis and granuloma size among mouse strains infected with Schistosoma mansoni. Am J Trop Med Hyg. 1987, 37: 85-97.","journal-title":"Am J Trop Med Hyg"},{"key":"193_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0167-0115(82)90059-3","volume":"3","author":"GE Peters","year":"1982","unstructured":"Peters GE: Distribution and metabolism of exogenous somatostatin in the rat. Reg Pept. 1982, 3: 361-369. 10.1016\/0167-0115(82)90059-3.","journal-title":"Reg Pept"},{"key":"193_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0167-0115(83)90252-5","volume":"5","author":"TL Peeters","year":"1983","unstructured":"Peeters TL, Janssens J, Vantrappen GR: Somatostatin and the interdigestive migrating motor complex in man. Reg Pept. 1983, 5: 209-217. 10.1016\/0167-0115(83)90252-5.","journal-title":"Reg Pept"},{"key":"193_CR19","first-page":"813","volume":"109","author":"MO Nishimura","year":"1985","unstructured":"Nishimura MO, Asahi M, Hayashi M, Takazono I, Tanaka Y, Kohda H, Urabe H: Extracellular matrix in hepatic granulomas of mice infected with Schistosoma mansoni (qualitative and quantitative analysis). Arch Path Lab Med. 1985, 109: 813-818.","journal-title":"Arch Path Lab Med"},{"key":"193_CR20","first-page":"855","volume":"48","author":"SS Mansy","year":"1998","unstructured":"Mansy SS, Yehia HA, Hassan MM, Hassan EA, Youssef MM, Hadi AA, Mackenzie CD: Effect of octreotide on the pathology of hepatic schistosomiasis. Arzneimittelforschung. 1998, 48: 855-861.","journal-title":"Arzneimittelforschung"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-45.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1471-2334-5-45\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-45","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-5-45.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:41:37Z","timestamp":1728304897000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-5-45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-5-45","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2005,6,10]]},"assertion":[{"value":"30 December 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"45"}}